Follow
Vis AN
Vis AN
Vumc
Verified email at vumc.nl
Title
Cited by
Cited by
Year
Prostate cancer detection at low prostate specific antigen
FH Schröder, I Van Der Cruijsen-Koeter, HJ De Koning, AN Vis, ...
The Journal of urology 163 (3), 806-812, 2000
4492000
Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with …
LMS Boevé, MCCM Hulshof, AN Vis, AH Zwinderman, JWR Twisk, ...
European urology 75 (3), 410-418, 2019
3602019
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome
BWG Van Rhijn, AN Vis, TH Van Der Kwast, WJ Kirkels, F Radvanyi, ...
Journal of clinical oncology 21 (10), 1912-1921, 2003
3592003
FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma
BWG Van Rhijn, TH Van Der Kwast, AN Vis, WJ Kirkels, ER Boevé, ...
Cancer research 64 (6), 1911-1914, 2004
2672004
Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non–muscle-invasive bladder cancer
BWG Van Rhijn, TCM Zuiverloon, AN Vis, F Radvanyi, ...
European urology 58 (3), 433-441, 2010
2142010
Prostate-specific antigen-based early detection of prostate cancer—validation of screening without rectal examination
FH Schröder, M Roobol-Bouts, AN Vis, T van der Kwast, R Kranse
Urology 57 (1), 83-90, 2001
1732001
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer
AN Vis, FH Schröder, TH van der Kwast
European urology 50 (2), 258-265, 2006
1652006
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Section Rotterdam: a comparison of two rounds of screening
R Postma, FH Schröder, GJLH van Leenders, RF Hoedemaeker, AN Vis, ...
European urology 52 (1), 89-97, 2007
1542007
Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles
D Koppers-Lalic, M Hackenberg, R De Menezes, B Misovic, M Wachalska, ...
Oncotarget 7 (16), 22566, 2016
1212016
Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam
IW Van Der Cruijsen-Koeter, AN Vis, MJ Roobol, MF Wildhagen, ...
The Journal of urology 174 (1), 121-125, 2005
1192005
Value of an immediate intravesical instillation of mitomycin C in patients with non–muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients
J Bosschieter, JA Nieuwenhuijzen, T van Ginkel, AN Vis, B Witte, ...
European urology 73 (2), 226-232, 2018
1132018
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways
AN Vis, FH Schröder
BJU international 104 (4), 438-448, 2009
1132009
The FGFR3 Mutation is Related to Favorable pT1 Bladder Cancer
BWG Van Rhijn, TH Van Der Kwast, L Liu, NE Fleshner, PJ Bostrom, ...
The Journal of urology 187 (1), 310-314, 2012
1122012
PROGNOSTIC VALUE OF CELL CYCLE PROTEINS p27kip1 AND MIB-1, AND THE CELL ADHESION PROTEIN CD44s IN SURGICALLY TREATED PATIENTS …
AN VIS, MA NOORDZIJ, K FITOZ, MF WILDHAGEN, FH SCHRÖDER, ...
The Journal of urology 164 (6), 2156-2161, 2000
1082000
Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy
AN Vis, MO Boerma, S Ciatto, RF Hoedemaeker, FH Schröder, ...
Urology 56 (4), 617-621, 2000
1002000
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features
JC Alers, PJ Krijtenburg, AN Vis, RF Hoedemaeker, MF Wildhagen, ...
The American journal of pathology 158 (2), 399-406, 2001
912001
Pathologic features of prostate cancer found at population-based screening with a four-year interval
RF Hoedemaeker, TH van der Kwast, R Boer, HJ de Koning, M Roobol, ...
Journal of the National Cancer Institute 93 (15), 1153-1158, 2001
822001
Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
BWG Van Rhijn, L Liu, AN Vis, PJ Bostrom, TCM Zuiverloon, NE Fleshner, ...
BJU international 110 (8), 1169-1176, 2012
762012
A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy
A Vis, A van der Gaast, B van Rhijn, T Catsburg, C Schmidt, G Mickisch
Cancer chemotherapy and pharmacology 49 (4), 342-345, 2002
732002
Staging prostate cancer
RF Hoedemaeker, AN Vis, TH Van Der Kwast
Microscopy research and technique 51 (5), 423-429, 2000
672000
The system can't perform the operation now. Try again later.
Articles 1–20